Second Chance for Moms Act

Hozzl · 2025-02-26T11:23:20Z

Explore the details of House Bill 796 Second Chance for Moms Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

2/26/2025, 11:23 AM

Summary of Bill HR 796

Bill 119 HR 796, also known as the "Mifepristone Labeling Act," aims to amend the Federal Food, Drug, and Cosmetic Act to require a warning label on mifepristone, a medication used for medical abortions, advising that its effects can be counteracted. The bill also seeks to amend the Public Health Service Act to establish a hotline that provides information to women seeking to counteract the effects of mifepristone.

The purpose of this legislation is to ensure that women who have taken mifepristone are aware that there is a potential option to reverse its effects. By requiring a warning label on the medication packaging, women will be informed of the possibility of counteracting the medication if they change their minds after taking it.

Additionally, the establishment of a hotline will provide women with access to information and resources on how to reverse the effects of mifepristone. This hotline aims to support women who may be seeking to reverse the effects of the medication and make an informed decision about their reproductive health. Overall, the Bill 119 HR 796 aims to provide women with more information and options regarding the effects of mifepristone, ultimately empowering them to make the best decision for their health and well-being.

Congressional Summary of HR 796

Second Chance for Moms Act of 2025

This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

Current Status of Bill HR 796

Bill HR 796 is currently in the status of Bill Introduced since January 28, 2025. Bill HR 796 was introduced during Congress 119 and was introduced to the House on January 28, 2025. Bill HR 796's most recent activity was Referred to the House Committee on Energy and Commerce. as of January 28, 2025

Bipartisan Support of Bill HR 796

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 796

Primary Policy Focus

Alternate Title(s) of Bill HR 796

To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.